{"nctId":"NCT00117286","briefTitle":"Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer","startDateStruct":{"date":"2005-03"},"conditions":["Prostate Cancer"],"count":57,"armGroups":[{"label":"Degarelix (60 mg to 160 mg)","type":"EXPERIMENTAL","interventionNames":["Drug: Degarelix"]},{"label":"Degarelix (80 mg to 160 mg)","type":"EXPERIMENTAL","interventionNames":["Drug: Degarelix"]}],"interventions":[{"name":"Degarelix","otherNames":["Degarelix acetate, FE200486"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has given written consent prior to any study-related activity being performed. A study-related activity is defined as any procedure that would not have been performed during the normal management of the patient.\n* Has completed study FE200486 CS14 through visit 22.\n\nExclusion Criterion:\n\n* Has been withdrawn from the FE200486 CS14 study.","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Participants With Markedly Abnormal Change in Vital Signs and Body Weight","description":"This outcome measure included incidence of markedly abnormal changes in blood pressure (systolic and diastolic), pulse, and body weight at the end of trial as compared to baseline. The table presents the number of participants in each group with normal baseline and markedly abnormal value post-baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"PRIMARY","title":"Liver Function Tests","description":"The figures present the number of participants who had abnormal (defined as above upper limit of normal range (ULN)) alanine aminotransferase (ALT) levels, aspartate aminotransferase levels, and bilirubin levels plus the number of participants who had ALT increases \\>3x ULN and ALT increases \\>3x ULN with concurrently increased bilirubin \\>1.5 ULN.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":30},"commonTop":["Hot flush","Fatigue","Injection site pain","Injection site nodule","Nasopharyngitis"]}}}